|Videos|October 25, 2021

US COVID-19, Flu Vaccine Prioritization Is Simpler Than Thought

Booster dose eligibility is broadening as the flu season approaches. An expert emphasizes the need to protect for both COVID-19 and the flu in the coming months.

Through 10-plus months of federal regulation, the availability of COVID-19 vaccines is still expanding. Developers are pursuing pediatric age group emergency use authorizations (EUAs) with the US Food and Drug Administration (FDA), and the agency just last week broadened the eligibility of booster doses to include adults who completed vaccination ≥6 months ago.

This comes at a time when influenza season is approaching as well—an outbreak risk that during last season’s third COVID-19 wave in the US was especially mild, but could be worse in 2021-22. More and more patients, today, are seeking vaccination for multiple respiratory viruses. But it’s simpler than it appears.

In an interview with Contagion, William Schaffner, MD, Professor of Preventive Medicine at the Vanderbilt University Medical Center, helped lay clear the messaging for COVID-19 and flu vaccination.

“The prioritization is pretty easy: if you haven’t got it, get it,” Schaffner said. “If you’ve received it and you’re due for a booster, get it. We need to keep pushing vaccination as much as possible. That’s absolutely fundamental.”

Schaffner additionally stressed the unpredictability of this flu season, as well as the state of COVID-19 boosters. As he noted, the epidemiological understanding of COVID-19 is still developing—but this may be the first iteration of an annual or semi-regular COVID-19 booster.

“We’re learning about the effectiveness and long-term protection of the vaccines. So stick with us; we don’t want to get too far ahead of our skis,” Shaffner said. “That said, the short answer is yes, this virus is going to be with us.”

Lastly, Schaffner discussed the overwhelming benefit of mRNA vaccines in COVID-19, and how the groundbreaking vaccine development has inspired preventive research in fields including influenza.

“We’ve been preoccupied (with COVID),” Schaffner said. “But there have been people in the laboratories shield from that day-to-day, who are working on other new mRNA vaccines, including against the flu.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.